- Home
- HL vs INCY Comparison
HL vs INCY Comparison
Compare HL & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HL | INCY |
|---|---|---|
| Founded | 1891 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3B | 17.0B |
| IPO Year | N/A | 1994 |
Fundamental Metrics
Financial Performance| Metric | HL | INCY |
|---|---|---|
| Price | $20.63 | $91.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 22 |
| Target Price | $20.71 | ★ $101.10 |
| AVG Volume (30 Days) | ★ 17.9M | 1.4M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 0.07% | N/A |
| EPS Growth | N/A | ★ 4173.33 |
| EPS | N/A | ★ 6.41 |
| Revenue | N/A | ★ $3,394,635,000.00 |
| Revenue This Year | $2.39 | $10.97 |
| Revenue Next Year | N/A | $10.24 |
| P/E Ratio | $44.94 | ★ $14.77 |
| Revenue Growth | N/A | ★ 13.67 |
| 52 Week Low | $4.46 | $53.56 |
| 52 Week High | $34.17 | $112.29 |
Technical Indicators
Market Signals| Indicator | HL | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 42.34 | 30.89 |
| Support Level | $20.47 | $82.66 |
| Resistance Level | $21.19 | $92.86 |
| Average True Range (ATR) | 1.30 | 2.52 |
| MACD | -0.25 | -0.71 |
| Stochastic Oscillator | 20.26 | 1.87 |
Price Performance
Historical ComparisonAbout HL Hecla Mining Company
Hecla Mining Co produces and explores silver, gold, zinc, and other metals. The operating business segments are Greens Creek, Lucky Friday, Keno Hill, and Casa Berardi. It generates maximum revenue from the Greens Creek segment. Geographically, It operates in Canada, the United States, and Mexico, and it derives a majority of its revenue from the United States.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.